Literature DB >> 27738886

Circulating periostin in patients with nonalcoholic fatty liver disease.

Stergios A Polyzos1, Jannis Kountouras2, Athanasios D Anastasilakis3, Athanasios Papatheodorou4, Panagiotis Kokkoris4, Evangelos Terpos5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27738886     DOI： 10.1007/s12020-016-1144-x

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  11 in total

1.  Periostin on the road to nonalcoholic fatty liver disease.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis
Journal:  Endocrine       Date:  2015-11-19       Impact factor: 3.633

2.  Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease.

Authors:  Stergios A Polyzos; Christos S Mantzoros
Journal:  Metabolism       Date:  2013-10-28       Impact factor: 8.694

3.  Deficiency of periostin protects mice against methionine-choline-deficient diet-induced non-alcoholic steatohepatitis.

Authors:  Yuan Li; Shasha Wu; Shanshan Xiong; Gaoliang Ouyang
Journal:  J Hepatol       Date:  2014-10-13       Impact factor: 25.083

4.  Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis; Jannis Kountouras; Polyzois Makras; Athanasios Papatheodorou; Panagiotis Kokkoris; Grigorios T Sakellariou; Evangelos Terpos
Journal:  J Bone Miner Metab       Date:  2015-06-09       Impact factor: 2.626

5.  Matricellular protein periostin contributes to hepatic inflammation and fibrosis.

Authors:  Yangmei Huang; Weiping Liu; Hongjun Xiao; Alaiyi Maitikabili; Qinghua Lin; Tiantian Wu; Zhengjie Huang; Fan Liu; Qi Luo; Gaoliang Ouyang
Journal:  Am J Pathol       Date:  2014-12-23       Impact factor: 4.307

6.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

Review 7.  Periostin, a multifunctional matricellular protein in inflammatory and tumor microenvironments.

Authors:  Allan Yi Liu; Hong Zheng; Gaoliang Ouyang
Journal:  Matrix Biol       Date:  2014-05-09       Impact factor: 11.583

Review 8.  Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines.

Authors:  Stergios A Polyzos; Jannis Kountouras; Christos Zavos
Journal:  Curr Mol Med       Date:  2009-04       Impact factor: 2.222

9.  Serum periostin is a potential biomarker for non-alcoholic fatty liver disease: a case-control study.

Authors:  Jin-Zhou Zhu; Hua-Tuo Zhu; Yi-Ning Dai; Chun-Xiao Li; Zhi-Yun Fang; De-Jian Zhao; Xing-Yong Wan; Yu-Ming Wang; Fang Wang; Chao-Hui Yu; You-Ming Li
Journal:  Endocrine       Date:  2015-09-11       Impact factor: 3.633

10.  Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index.

Authors:  Stergios A Polyzos; Jannis Kountouras; Athanasios Papatheodorou; Evangelia Katsiki; Kalliopi Patsiaoura; Efthimia Zafeiriadou; Evridiki Papadopoulou; Christos Zavos; Evangelos Terpos
Journal:  Ann Hepatol       Date:  2013 Sep-Oct       Impact factor: 2.400
View more
  1 in total

1.  Periostin Circulating Levels and Genetic Variants in Patients with Non-Alcoholic Fatty Liver Disease.

Authors:  Carlo Smirne; Violante Mulas; Matteo Nazzareno Barbaglia; Venkata Ramana Mallela; Rosalba Minisini; Nadia Barizzone; Michela Emma Burlone; Mario Pirisi; Elena Grossini
Journal:  Diagnostics (Basel)       Date:  2020-11-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.